Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Jody Aufrichtig
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 0
- Beta
- 1.31
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -73.96
Financials
Revenue
$0.00-100.0%Net Income
$-163.3KEBITDA
$-159.9KFree Cash Flow
$-412.7K-116924179.3%EPS (diluted)
$-0.01Shares Outstanding (diluted)
15.64M+838.3%Operating Expenses
$159.9KCash & Debt
$441.1KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-587.1K | $-0.04 |
| 2025 | $0.00 | $-400.2K | $-0.04 |
| 2024 | $0.00 | $-69.45M | $-0.52 |
| 2023 | $0.00 | $-6.08M | $-0.07 |
| 2022 | $0.00 | $-4.60M | $-0.05 |
| 2021 | $0.00 | $-92.5K | $-0.00 |
| 2020 | $0.00 | $-19.1K | $-0.01 |
| 2019 | $0.00 | $-13.3K | $-0.02 |
| 2018 | $0.00 | $-20.0K | $-0.04 |
| 2017 | $0.00 | $-54.8K | $-0.11 |
| 2016 | $0.00 | $-14.7K | $-0.03 |
Valuation
PSYGFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·1d ago·Neutral
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subje
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Psyence BioMed Announces Strategic Ibogaine Investment Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development Positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangements Designed to coordinate supply, manufacturing, regulatory and potential clinical development activities through a single U.S. entity with U.S.-based partners NEW YO
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
View source ↗
Congress trades
No disclosed congressional trades in PSYGF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.